Original Publication Date: 1 April, 2016
Publication / Source: Future Oncology
Authors: Gordon Alton & Santosh Kesari
Approximately 10,000 new cases of glioblastoma (GBM) are diagnosed each year in the USA . Most treatments are palliative in nature and do not alter the prognosis for the disease . As a result, the median survival time is only about 15 months . Even after extensive surgery to debulk the tumor, chemotherapy and radiation, the tumors invariably recur due to residual tumor-propagating cells that have been described as glioma stem-like cells (GSCs) [4,5].